← All trials
NCT07190222
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2025
- Primary completion
- Nov 27, 2029
- Completion date
- Jan 22, 2030
- First posted
- Sep 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 942
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SanofiLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.